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OBJECTIVES The purpose of this study was to determine the mechanism by which 60°C sauna treatment
improves cardiac function in patients with chronic heart failure (CHF).
BACKGROUND We have previously reported that repeated 60°C sauna treatment improves hemodynamic
data and clinical symptoms in patients with CHF. We hypothesized that the sauna restores
endothelial function and then improves cardiac function.
METHODS Twenty patients (62  15 years) in New York Heart Association (NYHA) functional class
II or III CHF were treated in a dry sauna at 60°C for 15 min and then kept on bed rest with
a blanket for 30 min, daily for two weeks. Ten patients with CHF, matched for age, gender
and NYHA functional class, were placed on a bed in a temperature-controlled (24°C) room
for 45 min as the nontreated group. Using high-resolution ultrasound, we measured the
diameter of the brachial artery at rest and during reactive hyperemia (percent flow-mediated
dilation, %FMD: endothelium-dependent dilation), as well as after sublingual administration
of nitroglycerin (%NTG: endothelium-independent dilation). Cardiac function was evaluated
by measuring the concentrations of plasma brain natriuretic peptide (BNP).
RESULTS Clinical symptoms were improved in 17 of 20 patients after two weeks of sauna therapy. The
%FMD after two-week sauna treatment significantly increased from the baseline value,
whereas the %NTG-induced dilation did not. Concentrations of BNP after the two-week
sauna treatment decreased significantly. In addition, there was a significant correlation
between the change in %FMD and the percent improvement in BNP concentrations in the
sauna-treated group. In contrast, none of the variables changed at the two-week interval in
the nontreated group.
CONCLUSIONS Repeated sauna treatment improves vascular endothelial function, resulting in an improve-
ment in cardiac function and clinical symptoms. (J Am Coll Cardiol 2002;39:754–9)
© 2002 by the American College of Cardiology Foundation
In patients with chronic heart failure (CHF), clinical
symptoms due to reduced peripheral perfusion, such as
muscle fatigue, heaviness in the limbs, edema, appetite loss
and constipation, are often observed (1). The sympathetic
nerve and renin-angiotensin system is activated to compen-
sate for a reduced cardiac output in CHF, resulting in
increased afterload and reduced peripheral perfusion (2).
Vasodilators, such as angiotensin-converting enzyme inhib-
itors, improve CHF largely by increasing peripheral perfu-
sion (3). We have applied thermal therapy through the
sauna, which also increases cardiac output and peripheral
perfusion (4,5), to patients with CHF and have found that
thermal therapy improves hemodynamic variables (5) and
clinical symptoms (6) in many of these patients. Experimen-
tal studies have demonstrated that CHF impairs
endothelial-dependent vasodilation of canine femoral arter-
ies (7) and rat hind-limb resistance vessels (8) in response to
acetylcholine, and in humans, peripheral resistance vessels
and large conduit vessels are also impaired in CHF (9–12).
One of the proposed mechanisms by which this occurs is
through decreased peripheral vascular production of
endothelium-derived nitric oxide (NO) in an animal model
of CHF (13) and in patients with CHF (14,15). This may
occur because of decreased shear stress due to reduced
peripheral perfusion (16). Shear stress is an important
stimulus for NO production (17–19) and the expression of
endothelial NO synthase (eNOS) (20,21). Furthermore,
several studies have shown that endothelial function in
patients with CHF is improved by treatment with
L-arginine (22,23), treatment with angiotensin-converting
enzyme inhibitors (24,25), physical training (26), adminis-
tration of dobutamine (27) or oral treatment with vitamin C
(28). However, it remains unproved whether restoration of
endothelial function can improve cardiac function in pa-
tients with CHF. Because thermal therapy increases cardiac
output and improves peripheral perfusion in patients with
CHF (5), we hypothesized that thermal therapy improves
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peripheral vascular endothelial function, resulting in im-
proved cardiac function.
METHODS
Study group. We studied 20 patients (age range 30 to 75
years, mean 62  15 years) with CHF; 17 of them (9 men
and 8 women) had idiopathic dilated cardiomyopathy and 3
(all men) had ischemic cardiomyopathy. Ten patients were
in New York Heart Association (NYHA) functional class
II, and the other 10 patients were in class III. The mean
cardiothoracic ratio (CTR) on chest radiography was 58 
7% (range 49% to 75%). The mean left ventricular ejection
fraction on echocardiography was 38  14% (range 15% to
54%). Ten patients with CHF, matched for age, gender and
NYHA functional class, were included in this study as the
nontreated group. All patients were receiving maintenance
doses of medications for heart failure, such as angiotensin-
converting enzyme inhibitors, diuretics and, in most cases,
beta-blockers and digitalis, and they were in stable clinical
condition for one month before study entry. Their medica-
tions had not been changed for at least two weeks before
and during this study. Written, informed consent was
obtained from all patients before participation, and the
protocol was approved by the Ethics Committee of the
Faculty of Medicine, Kagoshima University.
Sauna treatment. Because of its absence of hydrostatic
pressure, thermal therapy with a far infrared-ray dry sauna
was performed as previously reported (5). Patients were
placed in a supine position on a bed in a 60°C sauna for 15
min, and once removed, kept on bed rest with a blanket to
keep them warm for an additional 30 min. Patients were
weighed before and after the sauna treatment; oral hydra-
tion with water was used to compensate for lost weight. In
contrast, in the nontreated group, subjects were placed in a
supine position on a bed in a temperature-controlled (24°C)
room for 45 min.
Assessment of clinical symptoms. Clinical symptoms re-
lated to dyspnea, fatigue, edema, appetite loss, constipation
and insomnia were evaluated by a self-assessment quality-
of-life questionnaire. Each item had four grades: remarkably
improved, improved, no change or worsened. Patients were
classified into three groups based on the results of the
questionnaire. Patients who answered “improved” to more
than three items were defined as the improved group. Those
who answered “worsened” to at least one item were defined
as the worsened group. The others were defined as the
unchanged group.
Laboratory measurements. A fasting blood sample was
obtained in the morning to measure plasma levels of
neurohormonal factors, including catecholamines, atrial na-
triuretic peptide (ANP), brain natriuretic peptide (BNP),
thiobarbituric acid-reactive substances (TBARS) and tumor
necrosis factor-alpha (TNF-alpha). Plasma catecholamine
(norepinephrine, epinephrine and dopamine) concentra-
tions were measured with high-performance liquid chroma-
tography, and both plasma ANP and BNP concentrations
were measured with a radioimmunoassay. Plasma levels of
TBARS were measured with the thiobarbituric acid reac-
tion method, and plasma levels of TNF-alpha were mea-
sured with an enzyme-linked immunosorbent assay. Chest
radiography and echocardiography were also performed. For
calculating systemic vascular resistance, stroke volume was
measured by two-dimensional and pulsed-wave Doppler
echocardiography, monitoring heart rate and blood pressure
simultaneously.
Endothelial function. To evaluate endothelial function,
we used a previously described noninvasive ultrasound
method (29). Endothelial function was always assessed in a
temperature-controlled (24°C) laboratory before dinner.
The diameter of the brachial artery was measured on
B-mode ultrasound images, using a 12.0-MHz linear-array
transducer and high-resolution Doppler ultrasound system
(HDI-5000, ATL, Bothel, Washington). The ultrasound
images were recorded on a super-VHS videocassette re-
corder, and the arterial diameter was measured later with
ultrasonic calipers by two independent observers who had
not participated in the thermal therapy. After measurement
of blood pressure of the right arm, a pneumatic tourniquet
was placed around the left forearm (at a site distal to the
scanned part) and was inflated to a pressure of 20 mm Hg
over the systolic blood pressure for 5 min. During inflation,
we confirmed with photoplethysmography monitoring
(FCP-4731 IB-70, Fukuda Denshi, Kumamoto, Japan) that
no blood flow was present downstream of the tourniquet to
the second finger of the left hand. Reactive hyperemia was
calculated as the maximal flow in the first 15 s after cuff
deflation divided by baseline flow. Percent flow-mediated
dilation (%FMD) was defined as the percent change in
diameter between 60 s after cuff deflation and that on the
initial scan. Percent nitroglycerin (%NTG)-induced dilation
was also defined as the percent change in diameter between
4 min after administration of sublingual nitroglycerin spray
(300 g) and that on the initial scan. The vessel diameter
was measured by two observers who were unaware of the
clinical details and the stage of the study. The mean value of
the two observations was used. Interobserver variability was
determined by calculating the mean  SD of the difference
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in the two observers’ results from 20 arterial studies. In our
laboratory, the interobserver variability for measurement of
%FMD was 0.2 1.1%. In a preliminary study, when these
procedures were performed at the same time on two
different days in eight volunteers, the average intrasubject
test-retest difference for the measurements of %FMD was
0.1  0.8%.
Study protocol. Sauna therapy was performed once a day,
five days a week and for a total of two weeks in the
sauna-treated group. All examinations were performed be-
fore the first treatment and on the day after the last
treatment.
Statistical analysis. All data are expressed as the mean
value SD. Data at baseline and after sauna treatment were
compared by using the paired t test. The relationship
between the change in %FMD and the percent improve-
ment in BNP concentration was assessed by Spearman’s
correlation coefficients. A value of p  0.05 was considered
statistically significant.
RESULTS
Clinical findings and laboratory variables. The patients’
baseline clinical characteristics are shown in Table 1. All
patients enrolled in the study completed the study. None of
the sauna-treated patients experienced dyspnea, angina
pectoris or palpitations. Clinical symptoms were improved
in 17 of 20 patients (improved group) and were unchanged
in 3 patients (unchanged group) after the two-week sauna
therapy. However, no patient had worsened clinical symp-
toms. Although the mean heart rate and body weight did
not change, systolic blood pressure significantly decreased
the day after the two-week sauna treatment ended (Table
1). Furthermore, systemic vascular resistance significantly
decreased the day after the two-week sauna treatment
ended, as compared with baseline (2,267  640 dynes·s·
cm5 vs. 1,910  451 dynes·s·cm5, p  0.02). Laboratory
variables, including liver function, renal function, electro-
lytes and hematocrit, did not change after the two-week
sauna therapy (data not shown). In contrast, clinical symp-
toms, hemodynamic data and laboratory variables did not
change at the two-week interval in the nontreated group
(Table 1).
Vascular function. No patient showed any significant bra-
chial arterial stenosis or plaque. Before sauna and the day
after the two-week sauna therapy ended, the vessel diameter
of the brachial artery at rest had not changed significantly
(3.4  0.6 mm vs. 3.4  0.6 mm), and reactive hyperemia
was also unchanged (Table 1). The increase in %FMD
during the peak hyperemic response was maximal at 60 s
after release of the 5-min arterial occlusion. The increase in
%NTG-induced dilation was maximal at 4 min after ad-
ministration of NTG. In patients with CHF in the non-
treated group, %FMD and %NTG-induced dilation did not
change at the two week interval (Table 1). Two-week sauna
Table 1. Baseline Clinical Characteristics and Changes in Several Variables at the Two-Week Interval
Sauna-Treated Group
(n  20)
Nontreated Group
(n  10)
Comparison at
Baseline
Baseline After 2 Weeks p Value Baseline After 2 Weeks P Value p Value
Age (yrs) 62  15 64  16 0.74
Gender (M/F) 12/8 6/4 1.0
DCM/ICM 17/3 8/2 0.73
NYHA functional class (I/II/III) 0/10/10 1/14/5 0.01 0/5/5 0/5/5 1.0 1.0
Body weight (kg) 53.5  12.3 53.3  12.2 0.52 60.8  16.2 61.8  15.6 0.42 0.18
SBP (mm Hg) 107  22 97  17 0.019 112  14 111  14 0.87 0.52
DBP (mm Hg) 63  13 61  10 0.40 67  6 67  14 1.0 0.26
Heart rate (beats/min) 71  13 70  11 0.61 68  14 67  14 0.66 0.57
CTR (%) 58.2  7.1 55.9  7.9 0.002 56.2  4.4 56.3  4.5 0.59 0.42
LVEDD (mm) 59  8 57  9 0.047 60  7 59  8 0.42 0.74
LAD (mm) 46  9 45  10 0.17 41  8 41  8 0.18 0.15
Ejection fraction (%) 38  14 39  12 0.78 32  13 31  12 0.73 0.27
Norepinephrine (pg/ml) 426  234 432  333 0.91 464  185 467  259 0.97 0.66
Epinephrine (pg/ml) 31  36 32  34 0.94 28  13 29  19 0.84 0.74
Dopamine (pg/ml) 12  30 11  35 0.31 14  13 14  10 0.89 0.80
ANP (pg/ml) 107  101 90  94 0.34 111  104 116  112 0.75 0.92
BNP (pg/ml) 441  444 293  302 0.005 434  420 454  396 0.64 0.97
TBARS (pg/ml) 2.6  1.1 2.6  1.3 0.89 2.8  0.9 3.0  0.9 0.42 0.81
TNF-alpha (pg/ml) 1.4  0.8 1.6  1.7 0.65 1.4  1.8 1.3  1.6 0.90 0.65
%FMD (%) 4.4  2.5 5.7  2.5 0.0006 4.5  1.9 4.4  1.9 0.69 0.91
%NTG-induced dilation (%) 19.2  6.5 18.7  6.9 0.61 18.0  5.4 17.1  5.3 0.33 0.42
Hyperemia (%) 478  209 417  261 0.20 500  325 473  191 0.73 0.83
*Comparison with baseline values. Data are presented as the mean value  SD.
ANP  atrial natriuretic peptide; BNP  brain natriuretic peptide; CTR  cardiothoracic ratio; DBP  diastolic blood pressure; %FMD  percent flow-mediated dilation;
ICM  ischemic cardiomyopathy; DCM  dilated cardiomyopathy; LAD  left atrial dimension; LVEDD  left ventricular end-diastolic dimension; %NTG  percent
nitroglycerin; NYHA  New York Heart Association; SBP  systolic blood pressure; TBARS  thiobarbituric acid-reactive substances; TNF-alpha  tumor necrosis
factor-alpha.
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treatment significantly increased %FMD, as compared with
that before sauna therapy (4.4  2.5% vs. 5.7  2.5%, p 
0.0006) (Table 1). The data of each patient are shown in
Table 2. Percent FMD significantly increased from the
baseline value in the improved group (4.5  2.7% vs. 5.9 
2.5%, n  17, p  0.01), but not in the unchanged group
(4.2  1.7% vs. 4.0  1.6%, n  3). Percent NTG-induced
dilation was similar before and after the two-week sauna
treatment (19.2  6.5% vs. 18.7  6.9%) (Table 1).
Neurohormonal factors, TBARS and TNF-alpha.
Plasma concentrations of BNP after two weeks of sauna
treatment were significantly lower than those at baseline
(293  302 pg/ml vs. 441  444 pg/ml, p  0.005) (Table
1). However, ANP and catecholamine concentrations were
similar. Plasma levels of TBARS and TNF-alpha did not
change after two weeks of sauna therapy. In the nontreated
group, these concentrations did not change at the two-week
interval.
Variables assessed by chest radiography and echocardio-
graphy. The CTR on chest radiography decreased signifi-
cantly as compared with that at baseline (Table 1). On
echocardiography, the left ventricular end-diastolic dimen-
sion (LVEDD) decreased significantly as compared with
that at baseline (Table 1). However, there was no difference
in the ejection fraction. In contrast, CTR, LVEDD and
ejection fraction did not change at the two-week interval in
the nontreated group.
Correlation between endothelial and cardiac function.
We next examined the correlation between the variables of
cardiac function, including ejection fraction, LVEDD,
CTR, ANP and BNP, and %FMD of endothelial function
in the sauna-treated group. A significant correlation be-
tween the change in %FMD and the percent improvement
in plasma BNP concentrations was observed (r  0.69, p 
0.0005) (Fig. 1).
DISCUSSION
The present study indicates that two weeks of sauna therapy
improved endothelial function and decreased plasma BNP
concentrations in patients with CHF. Furthermore, there is
a correlation between the degree of improvement of %FMD
and the percent improvement in plasma BNP concentra-
Table 2. Characteristics of Each Patient in the Sauna-Treated Group
Patient
No. Diagnosis
Age (yrs)/
Gender
NYHA
Functional
Class
CTR
(%)
LVEDD
(mm)
BNP (pg/dl) %FMD (%)
Clinical
Symptoms
Before Sauna
Therapy
After 2 Weeks
of Sauna Therapy
Before Sauna
Therapy
After 2 Weeks
of Sauna Therapy
1 DCM 77/F III 62 52 258 207 5.4 6.4 Improved
2 DCM 75/F III 64 58 595 593 9.9 10.0 Improved
3 DCM 74/F II 66 59 89 75 5.5 5.1 Improved
4 DCM 50/F II 63 56 82 49 10.4 11.6 Improved
5 DCM 39/M II 54 70 51 41 2.4 3.0 Improved
6 DCM 70/M III 49 66 1,960 1,230 4.7 5.0 Improved
7 DCM 68/F II 65 67 377 222 4.9 7.7 Improved
8 DCM 58/M II 50 60 215 123 4.6 6.7 Improved
9 DCM 62/M III 60 72 998 879 5.1 5.0 Unchanged
10 DCM 44/M III 63 59 548 434 5.3 4.9 Unchanged
11 DCM 80/F III 75 58 475 187 4.2 8.0 Improved
12 DCM 75/M II 53 56 278 221 6.7 8.3 Improved
13 ICM 57/M II 45 52 46 48 2.3 2.2 Unchanged
14 DCM 70/F II 57 52 183 60 3.1 4.4 Improved
15 DCM 58/M III 55 60 304 228 2.3 4.4 Improved
16 DCM 60/F III 55 48 200 92 3.9 5.4 Improved
17 DCM 72/M II 55 53 315 347 4.2 3.7 Improved
18 ICM 72/M II 54 55 438 351 2.1 3.6 Improved
19 DCM 33/M III 66 78 939 249 0.6 2.5 Improved
20 ICM 73/M III 56 52 468 229 1.3 5.1 Improved
Abbreviations as in Table 1.
Figure 1. Relationship between the change in percent flow-mediated
dilation (%FMD) and the percent improvement in brain natriuretic peptide
(BNP) concentration in the sauna-treated group. There is a positive
correlation between the change in %FMD and the percent improvement in
BNP concentration before and after two weeks of sauna therapy (r  0.69,
p  0.0005).
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tions. Recent studies have indicated that plasma BNP
concentrations are an important marker of cardiac status
and prognosis in patients with heart failure (30–32). There-
fore, we conclude that repeated 60°C sauna therapy im-
proves peripheral vascular endothelial function, resulting in
an improvement in cardiac function in patients with CHF.
It should be noted here that body weight and hematocrit did
not change with sauna treatment.
Endothelial function and clinical symptoms. We clari-
fied that endothelial function significantly improved after
two-week sauna therapy in the brachial artery. We also
found that systemic vascular resistance significantly de-
creased after two-week sauna therapy, suggesting an im-
provement of endothelial function in resistance vessels.
Improved endothelial function leads to dilation of vessels by
an increase in NO production. The fact that two weeks of
sauna therapy significantly decreased systolic blood pressure
(Table 1) in the present study may reflect the improvement
in endothelial function. This results in decreased afterload
and, thus, increased cardiac output. These changes improve
peripheral circulation, which is probably responsible for the
improvement in clinical symptoms. Interestingly, in the
patients whose clinical symptoms improved, %FMD im-
proved significantly, whereas in the patients whose clinical
symptoms did not change, %FMD did not improve.
Possible mechanisms by which sauna therapy improves
endothelial and cardiac function. Recent studies have
indicated that endothelial function decreases in patients
with CHF (9–12). Two major mechanisms for this have
been proposed: 1) decreased NO production and 2) in-
creased degradation of NO. The eNOS protein is markedly
reduced in the thoracic aorta of dogs with pacing-induced
heart failure (33). Similar results have been reported in rats
with heart failure (34). In addition, Belch et al. (35)
reported that plasma lipid peroxides were significantly
higher in patients with CHF than in control subjects,
suggesting decreased NO bioavailability. In the present
study, we could not clarify the precise mechanisms by which
long-term sauna therapy improves endothelial function in
patients with CHF. However, we have previously demon-
strated that thermal therapy increases cardiac output in
patients with CHF (5). This results in increased peripheral
blood flow, which increases shear stress in the vessels. In
fact, we have recently found that blood flow of the brachial
artery significantly increases by 68% after 15 min of sauna
therapy and remains elevated by 51% at 30 min after sauna
therapy in patients with coronary risk factors (36). We
believe that this increase in shear stress leads to an increase
in NO production by the vessels. We have demonstrated
that repeated sauna treatment upregulates the eNOS pro-
tein in the arterial endothelium, including the aorta and
carotid, femoral and coronary arteries, of hamsters (37). In
the present study, we found that there was no difference in
plasma levels of TBARS before and after two weeks of
sauna therapy (Table 1). Therefore, it is likely that the
improvement in endothelial function after long-term, re-
peated sauna therapy is due to improved NO production by
eNOS upregulation in patients with CHF. We believe that
eNOS upregulation is due to a prolonged increase in shear
stress, but not decreased TNF-alpha levels (Table 1), which
is reported to downregulate eNOS expression (38). Further-
more, eNOS upregulation in the coronary artery may
directly improve cardiac function due to an increase in
coronary perfusion.
Effects of sauna treatment on natriuretic peptides. In
this study, plasma BNP concentrations significantly de-
creased after two-week sauna therapy, whereas plasma ANP
concentrations tended to decrease. We could not clarify the
precise mechanisms of this discrepancy. Although both
ANP and BNP concentrations are reported to be associated
with left ventricular dysfunction, recent studies have re-
vealed that BNP concentrations are more sensitive than
ANP concentrations (39,40). Therefore, one explanation
may be the shortness of the treatment period.
Clinical implications and study limitations. All patients
completed this study, and no patient had worsened clinical
symptoms, worsened cardiac arrhythmia, tachycardia, hypo-
tension or dehydration. Furthermore, this sauna therapy
may be applicable in patients with CHF who are unable to
exercise.
In the present study, we applied sauna therapy to patients
with CHF in NYHA functional class II or III and in a
stable clinical condition for one month before study entry.
Because there were stable patients with CHF, all variables,
including BNP concentrations and %FMD, did not change
at the two-week interval in the nontreated group. Further
studies are needed to investigate the beneficial effect of
sauna therapy on endothelial and cardiac function in pa-
tients with acute heart failure or NYHA functional class IV
CHF.
Conclusions. Repeated sauna treatment improves vascular
endothelial function, resulting in an improvement in cardiac
function and clinical symptoms.
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